白蛋白紫杉醇治疗晚期乳腺癌的多中心真实世界疗效与安全性研究
该多中心真实世界研究纳入2013—2019年203例接受白蛋白紫杉醇单药或联合方案治疗的晚期乳腺癌患者,中位无进展生存4个月、中位总生存14个月,客观缓解率36.0%、疾病控制率81.3%。各分子亚型及既往传统紫杉类治疗患者均显示疗效,早期使用预后更佳,不良反应以手足麻木为主且多可管理。
要点
- 白蛋白紫杉醇单药或联合方案对晚期乳腺癌各分子亚型均有效,总体ORR 36.0%、DCR 81.3%。
- 复发转移后一线或二线使用较三线以上使用总生存更长(22个月对11个月,P<0.001)。
- 常见不良反应为手足麻木(64.5%),多为Ⅰ~Ⅱ度(61.1%),整体可控。
核心结论
- 白蛋白紫杉醇单药或联合方案对晚期乳腺癌各分子亚型、传统紫杉类耐药及多线化疗失败患者仍有疗效,早期使用预后更佳,不良反应可控可管理。
研究设计与样本
- 多中心真实世界研究,收集2013—2019年中国医学科学院肿瘤医院、北京市朝阳区三环肿瘤医院、山东省肿瘤医院、郑州大学第一附属医院和河北大学附属医院接受白蛋白紫杉醇单药或联合方案治疗的晚期乳腺癌患者临床病理资料,共203例。
- 生存分析采用Kaplan-Meier法,生存率比较采用Log-rank检验。
主要发现
- 203例晚期乳腺癌患者中位无进展生存时间为4个月,中位总生存时间为14个月。
- 总体客观缓解率为36.0%,疾病控制率为81.3%。
- Luminal型、HER2过表达型及三阴性乳腺癌接受白蛋白紫杉醇治疗的ORR分别为37.3%、45.5%和31.0%,DCR分别为85.5%、68.2%和78.9%。
- 复发转移后白蛋白紫杉醇在一线或二线治疗与三线以上治疗患者比较,OS分别为22个月和11个月(P<0.001),ORR分别为44.9%和30.4%,DCR分别为87.2%和77.6%(P=0.018)。
- 既往接受过传统紫杉类治疗再次行白蛋白紫杉醇治疗的患者,ORR为35.8%,DCR为82.1%。
关键数值与推荐
- 全组常见不良反应为手足麻木,发生率为64.5%(131/203),其中Ⅰ~Ⅱ度患者占比61.1%(124/203)。
- 其他不良反应包括白细胞下降56.2%(114/203)、恶心呕吐36.9%(75/203)、血红蛋白下降21.2%(43/203)、血小板下降18.7%(38/203)和肝功能不全18.2%(37/203)。
临床怎么用
- 对于晚期乳腺癌各分子亚型患者,可考虑使用白蛋白紫杉醇单药或联合方案,尤其在复发转移后一线或二线早期使用可能获得更优生存。
- 既往接受过传统紫杉类治疗的患者仍可尝试白蛋白紫杉醇治疗。
- 治疗期间需关注手足麻木等不良反应,但整体可控可管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To observe the efficacy and safety of albumin-bound paclitaxel in the treatment of metastatic breast cancer. Methods: Multi-center data of patients who accepted single-drug albumin-bound paclitaxel or combination regimens from 2013 to 2019 were collected and the efficacy and safety were evaluated. Kaplan-Meier method was used for survival analysis, while Log-rank test was used to compare the survival rates. Results: A total of 203 advanced breast cancer cases were enrolled. The median progression-free survival time (PFS) lasted for 4 months, the median overall survival(OS)was 14 months, objective response rate (ORR) was 36.0% while the disease control rate (DCR) was 81.3%. The ORRs of Luminal, human epidermal growth factor receptor 2 (HER2) overexpression and triple-negative breast cancer patients underwent albumin-bound paclitaxel treatment were 37.3%, 45.5% and 31.0%, respectively, the DCRs were 85.5%, 68.2% and 78.9%, respectively. The OS of patients with relapse or metastasis who accepted less than two and more than two chemotherapy regimens were 22 months and 11 months (P<0.000 1), the ORRs were 44.9% vs 30.4%, DCRs were 87.2% vs 77.6% (P=0.018). The ORR and DCR of patients who accepted traditional paclitaxel treatment before the albumin-bound paclitaxel treatment were 35.8% and 82.1%, respectively. The common adverse reaction of these patients was numbness of limbs, which incidence rate was 64.5% (131/203), and 61.1% (124/203) were degree 1 to 2. Other adverse reactions including decreased white blood cells, which incidence rate was 56.1% (114/203); nausea and vomit, which incidence rate was 36.9% (75/203); anemia, which incidence rate was 21.2% (43/203); decreased platelet, which incidence rate was 18.7% (38/203); hepatic dysfunction, which incidence rate was 18.2% (37/203). Conclusions: Albumin-bound paclitaxel single or combination regimen is still significant efficient for various molecular subtypes of breast cancer patients or patients with traditional paclitaxel resistance or multi-line chemotherapy failure. Early usage has better prognosis, controllable adverse reaction and prominent clinical application value. 目的: 探讨白蛋白紫杉醇治疗晚期转移性乳腺癌的疗效及安全性。 方法: 收集2013—2019年于中国医学科学院肿瘤医院、北京市朝阳区三环肿瘤医院、山东省肿瘤医院、郑州大学第一附属医院和河北大学附属医院接受白蛋白紫杉醇单药或联合方案治疗的晚期乳腺癌患者的临床病理资料,评价患者的治疗疗效和安全性。生存分析采用Kaplan-Meier法,生存率的比较采用Log rank检验。 结果: 203例晚期乳腺癌患者中位无进展生存时间为4个月,中位总生存时间(OS)为14个月;客观缓解率(ORR)为36.0%,疾病控制率(DCR)为81.3%。Luminal型、人表皮生长因子受体2(HER-2)过表达型及三阴性乳腺癌接受白蛋白紫杉醇治疗的ORR分别为37.3%、45.5%和31.0%,DCR分别为85.5%、68.2%和78.9%。复发转移后白蛋白紫杉醇在一线或者二线治疗与三线以上治疗患者比较,OS分别为22个月和11个月(P<0.001),ORR分别为44.9%和30.4%,DCR分别为87.2%和77.6%(P=0.018);既往接受过传统紫杉类治疗再次行白蛋白紫杉醇治疗的患者,ORR为35.8%,DCR为82.1%。全组203例患者中,常见不良反应为手足麻木,其发生率为64.5%(131/203),Ⅰ~Ⅱ度患者占比61.1%(124/203);其他不良反应为白细胞下降(56.2%,114/203)、恶心、呕吐(36.9%,75/203)、血红蛋白下降(21.2%,43/203)、血小板下降(18.7%,38/203)和肝功能不全(18.2%,37/203)。 结论: 白蛋白紫杉醇单药或者联合方案对晚期乳腺癌各种分子亚型、传统紫杉类耐药、多线化疗失败的患者仍有疗效,早期使用预后更佳,不良反应可控可管理,具有良好临床应用价值。.
引用
- Sang D, Zhou H, Zong H, et al. [Multi-center real world study of the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced breast cancer]. Zhonghua Zhong Liu Za Zhi. 2021. PMID: 34695904. doi:10.3760/cma.j.cn112152-20201118-01001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。